Posted by Michael Wonder on 01 Aug 2023
Marinus Pharmaceuticals announces European Commission approval of Ztalmy (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder
31 July 2023 - Ztalmy is the first treatment approved by the European Commission for seizures associated with CDKL5 deficiency disorder in children and adolescents.
Marinus Pharmaceuticals today announced that the European Commission has granted approval of Ztalmy (ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase like 5 deficiency disorder in patients two to 17 years of age.
